Research Papers

25 of 309 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Enhanced broad spectrum in vitro antiviral efficacy of 3-F-4-MeO-Bn, 3-CN, and 4-CN derivatives of lipid remdesivir nuc…
McMillan RE; Lo MK; Zhang XQ; Beadle JR; Valiaeva N; Garretson AF; Clark AE; Freshman JE; Murphy J; Montgomery JM; Spiropoulou CF; Schooley RT; Hostetler KY; Carlin AF.
Antiviral Res (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and ma…
Nguyen HT; Chesnokov A; De La Cruz J; Pascua PNQ; Mishin VP; Jang Y; Jones J; Di H; Ivashchenko AA; Killian ML; Torchetti MK; Lantz K; Wentworth DE; Davis CT; Ivachtchenko AV; Gubareva LV.
Antiviral Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confe…
Jung HE; Ku KB; Kang BH; Park JH; Kim HC; Kim KD; Lee HK.
Antiviral Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors tha…
Chang YJ; Le UNP; Liu JJ; Li SR; Chao ST; Lai HC; Lin YF; Hsu KC; Lu CH; Lin CW.
Antiviral Res (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Antiviral activities of two nucleos(t)ide analogs against vaccinia, mpox, and cowpox viruses in primary human fibroblas…
Dsouza L; Pant A; Offei S; Priyamvada L; Pope B; Satheshkumar PS; Wang Z; Yang Z.
Antiviral Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
Driouich JS; Bernadin O; Touret F; de Lamballerie X; Nougairède A.
Antiviral Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
Cho J; Shin Y; Yang JS; Kim JW; Kim KC; Lee JY.
Antiviral Res (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Longitudinal analyses using <sup>18</sup>F-Fluorodeoxyglucose positron emission tomography with computed tomography as …
Cong Y; Lee JH; Perry DL; Cooper K; Wang H; Dixit S; Liu DX; Feuerstein IM; Solomon J; Bartos C; Seidel J; Hammoud DA; Adams R; Anthony SM; Liang J; Schuko N; Li R; Liu Y; Wang Z; Tarbet EB; Hischak AMW; Hart R; Isic N; Burdette T; Drawbaugh D; Huzella LM; Byrum R; Ragland D; St Claire MC; Wada J; Kurtz JR; Hensley LE; Schmaljohn CS; Holbrook MR; Johnson RF.
Antiviral Res (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters.
Cong Y; Mucker EM; Perry DL; Dixit S; Kollins E; Byrum R; Huzella L; Kim R; Josleyn M; Kwilas S; Stefan C; Shoemaker CJ; Koehler J; Coyne S; Delp K; Liang J; Drawbaugh D; Hischak A; Hart R; Postnikova E; Vaughan N; Asher J; St Claire M; Hanson J; Schmaljohn C; Eakin AE; Hooper JW; Holbrook MR.
Antiviral Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2.
Bills C; Xie X; Shi PY.
Antiviral Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mu…
Vanhulle E; Doijen J; Stroobants J; Provinciael B; Noppen S; Schols D; Stevaert A; Vermeire K.
Antiviral Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue infla…
Dichtl S; Diem G; Jäger M; Zaderer V; Lupoli G; Dächert C; Muenchhoff M; Graf A; Blum H; Keppler OT; Lass-Flörl C; Weiss G; Wilflingseder D; Posch W.
Antiviral Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes mu…
Kim JW; Heo K; Kim HJ; Yoo Y; Cho HS; Jang HJ; Lee HY; Ko IY; Woo JR; Cho YB; Lee JH; Yang HR; Shin HG; Choi HL; Hwang K; Kim S; Kim H; Chun K; Lee S.
Antiviral Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs.
Shekunov EV; Zlodeeva PD; Efimova SS; Muryleva AA; Zarubaev VV; Zarubaev VV; Slita AV; Ostroumova OS.
Antiviral Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Characterization of an air-liquid interface primary human vaginal epithelium to study Ebola virus infection and testing…
Escaffre O; Popov V; Hager E; Freiberg AN.
Antiviral Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2.
Zhu Y; Li M; Liu N; Wu T; Han X; Zhao G; He Y.
Antiviral Res (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Reverse genetic systems of SARS-CoV-2 for antiviral research.
Kurhade C; Xie X; Shi PY.
Antiviral Res (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Development of a rapid image-based high-content imaging screening assay to evaluate therapeutic antibodies against the …
Kota KP; Ziółkowska NE; Wei J; Peng J; Ordonez D; Raney C; Prigge J; Hooper JW; Awasthi M; Goebel SJ; Zabel BA; Nasar F; Lederman S; Bavari S.
Antiviral Res (Unknown)
Published: 2022
3/6 Transparent
Data
Targeting SARS-CoV-2 and host cell receptor interactions.
Lim SP.
Antiviral Res (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Current status of silica-based nanoparticles as therapeutics and its potential as therapies against viruses.
Tng DJH; Low JGH.
Antiviral Res (Unknown)
Published: 2022
2/6 Transparent
Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug disc…
Chiu W; Schepers J; Francken T; Vangeel L; Abbasi K; Jochmans D; De Jonghe S; Thibaut HJ; Thiel V; Neyts J; Laporte M; Leyssen P.
Antiviral Res (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the h…
Zhang YN; Zhang HQ; Wang GF; Zhang ZR; Li JQ; Chen XL; Hu YY; Zeng XY; Shi YJ; Wang J; Li YH; Li XD; Wang CH; Zhu B; Zhang B.
Antiviral Res (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Geneticin shows selective antiviral activity against SARS-CoV-2 by interfering with programmed -1 ribosomal frameshifti…
Varricchio C; Mathez G; Pillonel T; Bertelli C; Kaiser L; Tapparel C; Brancale A; Cagno V.
Antiviral Res (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404.
Fàbrega-Ferrer M; Herrera-Morandé A; Muriel-Goñi S; Pérez-Saavedra J; Bueno P; Castro V; Garaigorta U; Gastaminza P; Coll M.
Antiviral Res (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
Quindoline-derivatives display potent G-quadruplex-mediated antiviral activity against herpes simplex virus 1.
Frasson I; Soldà P; Nadai M; Tassinari M; Scalabrin M; Gokhale V; Hurley LH; Richter SN.
Antiviral Res (Unknown)
Published: 2022
3/6 Transparent
Funding Declared